Related Experiment Video
Updated: Nov 11, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Towards customized cancer vaccines: a promising filed in personalized cancer medicine
Xiaoling Xu1,2, Zichao Zhou2,3, Hui Li1,2
1Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital),Hangzhou City, China.
Introduction:
Cancer remains a major source of disease burden worldwide. Although cancer vaccines have been developed, most currently available cancer vaccines have limited therapeutic efficacy. Recent research using novel sequencing and bioinformatic tools has led scientists to realize that each tumor harbors a unique set of genetic mutations that can manifest as tumor-specific neoantigens. Therefore, it would be useful to develop personalized cancer vaccines that target neoantigens, which might improve the efficacy of these cancer treatments.
Areas Covered:
This review covers cancer vaccine development and the emerging field of personalized cancer vaccines, with a discussion of future clinical trials for this promising treatment strategy.
Expert Opinion:
Developing vaccines to treat tumors is one of the most promising and exciting fields in cancer research. However, cancer vaccines have shown limited efficacy in clinical trials for several decades, which may be related to the unique and complex processes underlying tumor development and progression. Recent studies have indicated that tumors express highly specific neoantigens, which are distinct from self-antigens. Thus, developing cancer vaccines that target these tumor-specific neoantigens is a promising strategy for developing personalized cancer vaccines.
Insights
Personalized cancer vaccines targeting unique tumor neoantigens show promise for improving cancer treatment efficacy. This approach may overcome limitations of traditional cancer vaccines by focusing on tumor-specific mutations.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Cancer represents a significant global health challenge.
- Current cancer vaccines exhibit limited therapeutic effectiveness.
- Tumor-specific neoantigens arise from unique genetic mutations.
Purpose of the Study:
- To review advancements in cancer vaccine development.
- To explore the emerging field of personalized cancer vaccines.
- To discuss the future of neoantigen-targeted cancer vaccines in clinical trials.
Main Methods:
- Literature review of cancer vaccine development.
- Analysis of novel sequencing and bioinformatic tools.
- Discussion of clinical trial strategies for personalized cancer vaccines.
Main Results:
- Personalized cancer vaccines target tumor-specific neoantigens.
- Neoantigens are distinct from self-antigens.
- Targeting neoantigens may enhance vaccine efficacy.
Conclusions:
- Personalized cancer vaccines targeting neoantigens offer a promising therapeutic strategy.
- This approach addresses limitations of traditional cancer vaccines.
- Future clinical trials are essential to validate this treatment modality.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

